Showing 321-330 of 333 grants
Title | Institution | Researcher | Program | Duration | Total Award Amount |
---|---|---|---|---|---|
Determination of Iatrogenic Hyperinsulinemia’s Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes | Vanderbilt University Medical Center (VUMC) | Justin Gregory | Improving Lives | 01-March-2020 to 30-June-2025 | $749.999,80 |
Clinical Validation of a Smart Bolus Calculator Informed by Insulin Sensitivity in Adults and Adolescents with Type 1 Diabetes | Rector & Visitors of the University of Virginia | Chiara Fabris | Improving Lives | 01-June-2020 to 31-December-2025 | $604.390,26 |
Islet autoantibody concordance and metabolic monitoring of individuals identified at risk for type 1 diabetes through population-based screening | Regents of the University of Colorado | Kimber Simmons | Cures | 01-July-2023 to 30-June-2026 | $750.000,00 |
T1 TRIDENT / Transformative Research in Diabetic Nephropathy | Trustees of the University of Pennsylvania | Katalin Susztak | Improving Lives | 01-September-2019 to 30-September-2024 | $191.795,06 |
JDRF and M-Diabetes Center of Excellence at the University of Michigan | Regents of the University of Michigan | Thomas Gardner | Cures | 01-October-2019 to 30-September-2025 | $7.795.943,05 |
JDRF T1D Coordinating Center | Jaeb Center for Health Research | Judy Sibayan | Transportfolio | 01-August-2019 to 31-August-2027 | $2.914.531,01 |
Identification of novel targets to increase human beta cell proliferation | The Regents of the University of California, San Francisco | Gregory Ku | Cures | 01-December-2020 to 30-June-2026 | $975.000,00 |
Defining the cell surface glycoproteome and glycome of human islets to enable single cell analysis of human β-cells | The Medical College of Wisconsin Inc. | John Corbett | Cures | 01-October-2022 to 30-September-2025 | $750.000,00 |
Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Patients | Mayo Clinic | Adrian Vella | Improving Lives | 01-October-2019 to 31-March-2025 | $437.405,39 |
Evaluation of the safety, tolerability, and general response to Lactobacillus johnsonii N6.2 in children and adolescents with T1D | University of Florida | Graciela Lorca | Cures | 01-September-2019 to 31-August-2026 | $355.941,78 |